ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO579

Population Frequency of Undiagnosed Pathogenic Variants in PKD Type 1 and Type 2

Session Information

Category: Genetic Diseases of the Kidneys

  • 1201 Genetic Diseases of the Kidneys: Cystic

Authors

  • Varughese, Santosh, The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Melbourne, Victoria, Australia
  • Savige, Judith A., The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Melbourne, Victoria, Australia
Background

The estimated population frequency of AD polycystic kidney disease in recent epidemiologic studies has varied from one in 1000 to one in 2000 but when based on a genetic analysis is closer to one in 1000 (PMID:30135240). This study has reexamined the commonest genes affected, PKD1 and PKD2, for pathogenic variants including assessing missense changes with highly stringent criteria, with Alamut and REVEL, in order to more accurately determine the ADPKD population frequency.

Methods

PKD1 and PKD2 variants were downloaded from gnomAD v2.1 and annotated in ANNOVAR. Structural and null variants were considered pathogenic and missense variants assessed for pathogenicity based on rarity, positivity in three computational tools and whether they affected a residue conserved in vertebrates. The occurrence of these variants in people of different ancestries was also examined. Our approach for assessing missense variants was compared with positivity in Alamut (scores >5 or >6), and REVEL (>0.932), and the accuracy of these approaches evaluated using 20 benign and 20 pathogenic variants reported in LOVD.

Results

One in 1500 of the population have a null PKD1 variant and one in 2500 have a null variant in PKD2. Thus the population frequency of null variants is greater than one in 1000 (8/7500) and 60% of variants affect PKD1. Null variants are most frequently found in people of African/African American, East Asian and South Asian ancestries.

Our strategy for assessment of missense changes in PKD1 had a sensitivity of 65% and a specificity of 95%, and missense changes in PKD2 had a sensitivity of 40% and specificity of 100%. However the population frequencies of missense variants were more variable with different approaches.

Conclusion

These results suggest that PKD1 and PKD2 pathogenic null and missense variants occur more often in the population than the previously-estimated one in 1000. Missense changes in PKD1 and PKD2 remain difficult to evaluate accurately for pathogenicity.

Population frequencies of predicted pathogenic structural, null and missense variants and strategy evaluation
 PKD1SensitivitySpecificityPKD2SensitivitySpecificity
Structural and null variants
Total null and structural variants70 or one in 1500 44 or one in 2500 
Comparison of evaluation of missense variants
Our assessment569 or one in 17865%95%81 or one in 135740%100%
Alamut > or equal to 5One in 18355%100%One in 122155%90%
Alamut > or equal to 6One in 140020%75%One in 238920%100%
REVEL > 0.932One in 52,5340%100%One in 18,31825%100%